Table 2.

Administration schemes of elotuzumab-based regimen

Study	Phase	Regimen
Elotuzumab with Imids regimens
Lonial 201521	3	Elotuzumab 10 mg/kg IV d1,8,15,22 cycles1–2 and then d 1,15 for subsequent cycle Lenalidomide 25 mg PO d 1–21 Dexamethasone 40 mg PO/week or 28 mg/week PO with 8 mg IV on elotuzumab dosing days
Dimopoulos 201822	2	Elotuzumab 10 mg/kg IV d1,8,15,22 cycles 1–2 and 20 mg/kg IV d1 cycle 3 and Beyond Pomalidomide 4 mg PO d1-21 Dexamethasone 40 mg (patients ≤75 years) or 20 mg (patients >75 years) per week, except on the days of elotuzumab 28 mg PO in patients ≤75 years or 8 mg PO in patients >75 years) and 8 mg IV
Mateos 201623	2	Elotuzumab 10 mg/kg IV d 1,8,15,22 x2 cycles then d 1,15 Thalidomide 50 mg escalated to 200 mg/d PO Dexamethasone split dose of 28 mg PO and 8 mg IV at least 45 mins before the infusion; 40 mg PO on days without elo; 28-day cycles ±cyclophosphamide 50 mg/d PO
Elotuzumab with PI regimens
Jakubowiak 201224	1	Elotuzumab 2.5–20 mg/kg IV Bortezomib 1.3 mg/m2 IV d 1,4,8,11; 21-day cycles
Jakubowiak et al. 201625	1/2	Elotuzumab 10 mg/kg/weekly first 2 cycles, on days 1 and 11 during cycles 3–8 and on days 1 and 15 thereafter Bortezomib 1.3 mg/m2 IV or SC d 1,4,8,11 during cycles 1–8 and on days 1,8,15 thereafter Dexamethasone 20 mg PO on non-elotuzumab dosing days, and 8 mg PO plus 8 mg IV on elotuzumab dosing days.

Abbreviations: d, day; IV, intravenous; PO, per os.